Objective: Determine the effect of a matrix metalloproteinase inhibitor (MMPi) and angiotensin converting enzyme inhibitor (ACEi) on collagen, MMP, tissue inhibitors of MMPs (TIMPs) expression in the spontaneously hypertensive heart failure (SHHF) rat. Methods: Six groups were tested: normotensive 9-and 13-month-old Wistar-Furth (WF) rats, 9-month-old SHHFs (compensatory hypertrophy), ACEi (quinapril, 10 mg kg day ) for 4 months. Collagen volume fraction was assessed histomorphometrically. Left ventricular (LV) mRNA [MMP-1,-2,-3,-7,-9,-11,-13,-14; TIMP-1,-2,-3,-4; and collagen a1(I) and a1(III)] and protein (MMP-2 and MMP-9 zymographic activity; Western blot analysis of MMP-13, and TIMP-1,-2,-4) levels could be quantified. Results: Collagen mRNA levels were elevated in SHHFs compared to age-matched controls, but collagen volume fraction was elevated only in 13-month-old SHHFs (|23). Only MMP-2 mRNA levels increased significantly with HF. However, MMP-2 and MMP-9 zymographic activity, and MMP-13 protein levels increased. TIMP-1 and TIMP-2 mRNA and protein levels increased, and TIMP-4 protein levels decreased in SHHFs vs. controls. Both drug treatments reduced LV dilation; preserved systolic function; and normalized MMP/ TIMP expression. Both drug treatments also reduced collagen volume fraction, but only quinapril reduced collagen mRNA levels and LV hypertrophy. Conclusions: The divergent effect of MMPi and ACEi on collagen mRNA levels and hypertrophy indicate that drug efficacy is mediated by different pathways in the SHHF rat.
Introduction
. MMPs are upregulated in the failing heart of both animals and man [16, 29, 34] . In addition, protein Left ventricular (LV) dilation, a common characteristic levels of the endogenous tissue inhibitors of matrix of remodeling in systolic heart failure (HF), has been metalloproteases (TIMPs) are decreased in hearts from shown to advance LV dysfunction, and to be related to the transplant patients which presumably also contributes to onset of morbidity and mortality in HF patients [7, 22, 28] .
increased cardiac MMP activity [16] . MMP inhibition also Dilation appears to have a causal role in the evolution of reduces LV dilation in animal HF models [18, 21, 26] as LV dysfunction. However, the molecular mechanisms well as myocardial infarction [10, 24] . Angiotensin convertmediating LV chamber dilation are still being elucidated.
ing enzyme inhibitors (ACEi) also reduce LV dilation, but Matrix metalloproteinases (MMPs) have the predominant by a poorly understood mechanism(s). role in hydrolyzing extracellular matrix proteins, and have
We have previously reported that the MMP-inhibitor been proposed to mediate collagen degradation leading to (MMPi), PD166793, blocks LV dilation and preserves LV LV dilation [24, 26] , and ultimately to heart failure (HF) systolic function in the spontaneously hypertensive heart failure (SHHF) rat [21] , an inbred line derived from an initial cross between SHR and Zucker strains. MMP-1 has 21 been reported to be increased in the SHR [3] as well as 50 mg kg , IP) prior to testing, and ventilated with 50% MMP-2 and MMP-12 [20] . The protein level of a TIMP oxygen. LV pressure was measured in closed-chest rats has also been reported to be decreased in SHRs [20] , using a Millar pressure transducer (Houston, TX) inserted although given the technique used (reverse zymography) it via the right carotid. Data was recorded at 500 Hz on a is not clear which isoform. MMP/ TIMP expression has not digital data acquisition system (Gould Po-Ne-Mah HD-4, been characterized in the SHHF rat, nor has the effect of Valley View, OH). A 30-s average was used for baseline drug treatment on gene expression been characterized.
hemodynamic measurements. Accordingly, we compared the expression of MMPs (-1,-
The heart was arrested with an intravenous administra-2,-3,-7,-9,-11,-12,-13,-14), TIMPs (-1,-2,-3,-4), and coltion of KCl, and rapidly excised. Cardiac dilation was lagen [a1(I),a1(III)] in SHHF vs. normotensive rats as measured by generating ex vivo left ventricular pressure well as the effect of MMPi and ACEi treatment on mRNA volume (PV) curves. The PV curves were generated by levels. Protein level determinations were made where evacuating the LV chamber of saline, and then filling the antibodies which worked on rat samples were available for LV at a fixed rate using a programmable pump set at a 1
21
MMPs (-13) and TIMPs (-1,-2,-4). The lack of antibodies ml min flow-rate. The LV was then frozen in liquid N 2 was not expected to be a major limitation because MMP for subsequent biochemical analysis. expression has been reported to be transcriptionally mediated [32] . ACEi treatment has been reported to increase 2.3. Northern analysis and RNA protection assay MMP-1 expression in SHRs thus reducing fibrosis [3] . Both ACEi and MMPi treatment have been reported to Total RNA was extracted from frozen left ventricular have no effect on MMP expression in the paced pig [18] . tissues using Trizol, (Gibco-BRL, Gaithersburg, MD). Therefore, it was expected that there would be: (1) a
Northern blots were made with 20 mg of total RNA using a progressive increase in MMP expression in vehicle-treated technique described in detail elsewhere [13] . AutoradiogSHHFs that paralleled LV dilation observed in this model; raphy was performed by exposure to a Kodak film at (2) a decrease in TIMP expression based on similar 2808C for 24-48 h. To control the variations in sample observations in the failing human heart [16] ; (3) mRNA loading, a mouse glyceraldehyde-3-phosphate dehydrogenand protein level changes would parallel each other; and ase (GAPDH) cDNA fragment (Ambion, Austin, TX) was (4) MMPi treatment would not directly effect gene expresused to normalize all blots. The probes used for this study sion given that this drug inhibits the catalytic site of an were the cDNA fragments flanking the coding sequence, extracellular enzyme.
including human MMP-1 (ATCC, MD); rat MMP- RNA protection assays (RPA) were performed to detect (N512) and 13-month-old (N513) WF rats, 9-month-old low copy genes using a protocol described in detail (N511) SHHF rats with compensatory hypertrophy, 13-elsewhere [13] . Total RNA (10 mg) was analyzed with an month-old (N59) SHHF rats with overt HF, and 13-RPA II kit (Ambion, Austin, TX). Anti-sense RNA probes month-old SHHF rats treated with PD166793 (SHHF-793, were generated from the restriction enzyme linearized N512) or quinapril (SHHF-Q, N510). PD166793 was plasmids with MAXIscript SP6 / T7 kit (Ambion, Austin, 21 21 administered as a 5 mg kg day dose, and quinapril as 32 TX). The hybridization between P -RNA probe and RNA 21 21 a 10 mg kg day dose in chow. All rats were mainwas carried overnight at 458C. RNase digestion was tained on a chow diet (Purina, No. 5002) for the duration performed for 30 min at 378C, after which protected RNA of the study (4 months), and had ad libitum access to food hybrids were extracted with pheno / chloroform, precipiand water. This study was approved by the Parke-Davis tated with ethanol. Ribonuclease protection products were Animal Care and Use Committee, and the animal research electrophoresed, and the gel exposed to Kodak BioMax protocol conformed to the guide for the Care and Use of film to visualize product. Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Gelatin and casein zymography 2.2. Cardiovascular assessment
Protein samples containing MMP activity were extracted Rats were anesthetized with sodium pentobarbital (25- from the same set of samples used for RNA analysis.
Frozen LV tissues (|50 mg) were homogenized in 1 ml of 2.6. LV morphometry ice-cold lysis buffer containing 150 mM NaCl, 20 21 21 mmol L Hepes, 0.2 mmol L EDTA, 25% glycerol and LV circumferential sections (2 mm) were maintained in protease inhibitor (complete, Boehringer Mannheim). fixative for 48 h and then embedded in paraffin. FiveHomogenates were then aliquoted and stored at 2808C micron sections were stained with picrosirius red for until use. MMPs activities were detected using a gelatin or fibrillar collagen measurements. Stained sections were casein containing substrate gel as previously described imaged using polarized light which causes clear demarca- [19] . Extracts were thawed on ice, and the volume of 30 tion of the fibrillar collagens [35] . LV cross-sections were mg of protein was adjusted to 10 ml, then mixed with an divided into eight equal sections, digitized using a 103 equal volume of 23 SDS gel sample loading buffer. After objective, and analyzed (Image Pro Plus, Media Cyberelectrophoresis, the gel was incubated with renaturing netics, Silver Spring, MD). Percentage area of extracellular buffer and developing buffer at room temperature for 30 staining was computed from 15 to 24 random fields min each, then changed to fresh developing buffer once spanning the entire thickness of the LV wall thus providing and incubated at 378C for 18 h (gelatin), or 48 h (casein).
a composite measure of interstitial, perivascular, and The amount of LV protein loaded per lane for zymography replacement fibrosis. (30 mg), and the development time used for gelatin zymography was within the linear range for measuring 2.7. Data analysis pro-and active-form gelatinase activity based on doseresponse work done with recombinant MMPs (unpubl.
All the autograms and zymograms were scanned using a obs.), and the results of Kleiner and Stetler-Stevenson [14] .
densitometer and analyzed by image quantitation software Gelatin gels were stained with Coomassie Brilliant Blue (Molecular Dynamics, Ver. 4.2a, Sunnyvale, CA). All data (0.2%). Clear lytic zones indicated the presence of MMP are expressed as the mean6S.E.M. Physiological data was enzymes. A separate set of gelatin and casein gels were analyzed using a one-way analysis of variance to test for developed in the presence of 20 mM EDTA; inhibition of treatment effects, and between-groups differences were lysis was used as a marker of MMP specific activity.
assessed using a post hoc t-test (SAS v6.12, SAS Institute). RNA and zymography data was analyzed by ANOVA 2.5. Western blot analysis based on the ranks of the data because there was a significant departure from normality. Statistical signifi-LV tissue extracts containing 40 mg total protein were cance was based on a P value#0.05. electrophoresed on a 4-20% Tris-glycine gel, and then transferred onto a nitrocellulose filter. After blocking, the filter was incubated with diluted antibody and matched 3. Results secondary antibody. Protein bands were visualized using an ECL mixture (NEN Life Science Products, Boston,
In vivo hemodynamic and pressure-volume measure-MA). Blots were stripped, and this process repeated with a ments are summarized in Table 1 . There were no differsecond antibody. All antibodies were obtained from ences in LVESP, or LV function and geometry between the Chemicon (Temecular, CA). Two sets of blots were 9-and 13-month-old WF rats. LVESP was higher, but LV prepared. The first set was used to measure MMP-13 1dP/dt was not significantly different in the 9-month (MAB3321, 1:2000) and TIMP-4 (AB816, 1:1000). The SHHF rats compared to either WF group. LVESP was second set was used to measure TIMP-1 (AB800, 1:1000) reduced in 13-month-old SHHFs from 9-month values. and TIMP-2 (AB801, 1:1000).
13-month-old SHHFs showed a 50% reduction in LV Table 1 Alterations of LV volume at a fixed pressure of 20 mm Hg (LVV), the rate of LV pressure increase (1dP/dt), LV weight (LVW), LV end-systolic pressure (LVESP), and LV gene expression during the development of heart failure in the SHHF rats as compared to normotensive WF rats, 1dP/dt compared to either 9-month-old SHHFs or WF SHHF-9 group. Fig. 3 shows Northern blots of MMPs rats. SHHFs treated with the MMPi, PD166793, from 9 to using representative samples from each group illustrating 13 months showed a maintenance of LVESP. LVESP was that MMP-2 had a between-group elevation in mRNA significantly lower in the quinapril-treated 13-month-old levels. SHHFs compared to the MMPi-treated group. LV 1dP/ dt MMP-2 and MMP-9 zymographic activity was upreguin both drug treatment groups was comparable to 9-monthlated in the compensatory hypertrophy (SHHF-9) and the old SHHFs.
failing (SHHF-13) LV (Table 2 ). Fig. 2 shows a gelatin LV mass was elevated in all SHHF groups compared to zymogram of representative animals. MMP-2 activity is both WF normotensive groups. LV weight was significantly evident by the lytic bands at the 72-kD (pro-form) and the greater in the 13-month-old MMPi-treated group compared 66-kD (active-form) regions, and MMP-9 activity at the to the 9-month-old SHHFs and 13-month-old quinapril-92-kD region (pro-form). A lytic band representing the treated SHHF. This data indicates that progressive hyactive form of MMP-9 (84-kD) was not observed in this pertrophy occurred in the MMPi group, but not in the study. There was a progressive increase in the active form quinapril-treated SHHFs.
(66-kD band) of MMP-2 in SHHF-9 (factor of 1.860.2) LV volume at 20 mm Hg was used as a measure of and SHHF-13 (factor of 4.760.5) rats compared to agedilation. LV volume did not change with age in normotenmatched controls. Fig. 4 also shows that the basal level of sive WF rats. LV dilation was present in 9-month-old MMP-9 protein is quite low in normal animals, and a SHHF rats with normal LV function. This dilation inprogressive increase of MMP-9 activity occurred in SHHFcreased further in untreated 13-month SHHFs, but was 9 (factor of 1.760.2) and SHHF-13 (factor of 3.960.7) significantly reduced in both age-matched drug groups rats compared to age-matched controls. Lytic band density compared 13-month-old untreated SHHFs.
for pro-and active form of MMP-2 increased in SHHF-13 rats. Both drug treatments reduced MMP-2 active-form activity compared to age-matched vehicle controls. MMP-3.1. LV collagen mRNA and morphometry inhibition also reduced the pro-form of MMP-2 (72-kD band), and MMP-9 compared to SHHF-13. The MMP-2 Fig. 1 shows representative micrographs of picrosirius results are consistent with the MMP-2 mRNA level red stained LV cross-sections from a 9-month-old norchanges. The disparity between MMP-9 mRNA and motensive rat as well as each SHHF group. Collagen zymography data may be due to a greater sensitivity of volume fraction was not different between 9-and 13-zymography vs. Northern analysis, or to a post-transcripmonth-old normotensive rats, and 9-month-old SHHFs as tional effect causing an increase in MMP-9 accumulation. shown in the top middle panel of Fig. 1 . The collagen MMP-3,-7 and -13 protein levels were assessed using volume fraction increased about two-fold in untreated casein zymography, but no EDTA sensitive banding was 13-month-old SHHFs. Total collagen volume fraction was observed. A Western blot analysis of MMP-13, however, reduced in both quinapril and MMPi treatment compared revealed that 13-month-old untreated SHHF rats showed a to 13-month-old vehicle-treated SHHFs. Both collagen significant increase in MMP-13 protein levels compared to a1(I and III) mRNA levels increased comparably in normotensive WF rats or 9-month-old SHHFs (Fig. 5 ). untreated 9-and 13-month-old SHHF rats compared to Both PD166793 and quinapril reduced MMP-13 protein normotensive WF rats (Fig. 2) . Quinapril significantly levels. reduced collagen a1(I) mRNA levels while MMPi had no effect on mRNA levels of either collagen subtype.
TIMP expression 3.2. MMP expression
All four TIMP mRNAs were quantifiable in the rat LV All mRNA levels were normalized to GAPDH in this by Northern analysis (Fig. 6 ). TIMP-1 and TIMP-2 mRNA study. Some genes had LV mRNA expression levels too and protein levels were significantly higher in both 9-and low for assessment by Northern (MMP-3,-7,-9,-11 and 13-month-old SHHFs compared to age-matched normoten--13). Alterations in low copy gene expression were also sives (Table 3) . TIMP-1 mRNA and protein levels inassessed by RPA (MMP-3) or RT-PCR (MMP-7,-9,-11).
creased progressively with age in SHHFs. No between The expression of the following MMPs was found to be group differences were observed for TIMP-3 and TIMP-4 unchanged: MMP-3,-7,-9,-11,-12,-13 and -14. No evidence mRNA levels. However, TIMP-4 protein levels in 9-and was found that the rat heart expresses MMP-1 by Northern 13-month-old SHHFs was half that of age-matched noranalysis, RPA, or RT-PCR. MMP-2 mRNA levels were motensive controls (Table 3) . Both MMPi and quinapril significantly increased in 13-month-old (factor of 2.760. 2) treatment significantly decreased TIMP-1 mRNA levels as but not 9-month-old (factor of 1.260.2) SHHFs compared well as TIMP-1 and TIMP-2 protein levels compared to to age-matched normotensive controls (Table 2 ). MMPi 13-month-old non-drug-treated SHHFs. Both drug treatand quinapril reduced MMP-2 mRNA levels to that of the ments normalized TIMP-4 protein levels. .05 compared to age-matched WF SHHF-13 with overt heart failure, and age-matched 13-month-old SHHF group; †, P#0.05 compared to SHHF-13.
treated with MMPi (SHHF-793) or the ACE-inhibitor, quinapril (SHHF-Q). Samples from the same rat are shown in each blot. Only MMP-2 exhibited a between-group elevation in mRNA levels.
Discussion
The important findings in the current study are four-fold: (1) MMPi as well as quinapril treatment reduced fibrosis; (2) we identified which MMPs increased (MMP-2,-9,-13) and which TIMPs decreased (TIMP-4) during compensatory hypertrophy and HF; (3) MMP/ TIMP protein levels can be altered in the hypertrophied and failing heart without a significant change in mRNA levels (MMP-2,-9,-13 and TIMP-4); and (4) both drug treatments reduced LV dysfunction and remodeling as well as MMP/ TIMP ex- [9]. This observation, and the efficacy of MMPi supports the role of MMP-mediated LV dilation in the transition between LV hypertrophy and HF. quinapril in this study was not unexpected given previous demonstrations of this in SHRs [3, 17] a parental line used 4.1. Collagen expression and accumulation to create the SHHF. Two other potential mechanisms mediating this ACE-inhibitor effect are decreased anCollagen type I mRNA and fibrosis reduction by giotensin type I receptor stimulated secretion of TGFb [4] , Table 2 Alterations in MMP-2 based on Northern analysis, and MMP-2 and MMP-9 activity by zymography in SHHF rats as compared to normotensive WF rats, d
and 13-month-old SHHFs treated with either the MMPi PD166793 (SHHF-793), or quinapril (SHHF-Q) for 4 months WF-9 WF-13 SHHF-9 SHHF-13 SHHF-793
compared to untreated 13-month-old SHHFs -despite a lack of an effect on collagen mRNA levels. Cardiac collagen deposition is controlled by non-MMP dependent post-translational system(s) such as lysosomal degradation, fibril secretion, and trimeric collagen assembly [2] . Collagen volume fraction in this study represented the sum of perivascular, interstitial, reactive and replacement fibrosis. Therefore, the lesser degree of fibrosis may reflect an where [10] .
MMP upregulation
MMP-2 and MMP-9 zymographic activity, and MMP-13 protein levels were significantly greater in SHHFs compared to normotensive age-matched controls. MMP-2 and MMP-9 zymographic activity also increased progressively with age in SHHFs. The upregulation of MMP-2 activity in the current study agrees with results reported for SHRs [20] as well as human HF patients [16, 29] . Several previous rat studies have reported that MMP-1 is upregulated during hypertension [3, 23, 25] . However, these studies either indirectly measured MMP-1 [3, 23] , or potentially measured rat collagenase (MMP-13) rather than MMP-1 [25] . In this study MMP-13 (collagenase-3) appears to act in concert with the gelatinases in the elevated turnover of extracellular matrix proteins during HF progression. matrix protein enhances MMP-2 enzyme stability as well as its activity [12] . Therefore, fibrosis may also initiate and an upregulation of MMP-1 [3] in SHRs. Although the collagen degradation by causing MMP accumulation. current study does not address the role of angiotensin or Three potential factors involved in increasing MMP TGFb, it does indicate that MMP-induced fibrinolysis does mRNA levels in HF are cytokines, inflammatory cell not account for lower LV collagen in quinapril-treated infiltrate, and cytoskeletal remodeling. A variety of cytoSHHFs.
kines (e.g. TNFa, IL-1b) have been shown to increase Surprisingly, MMPi significantly lowered LV collagen MMP mRNA levels [31] . TNFa levels have been reported to be elevated in the SHHF rat [1] . MMP-9 has typically days post-MI significantly reduces LV dilation [27] . It is possible that this effect in humans is mediated by ACEbeen found to be associated with inflammatory rather than inhibitor-induced changes in MMPs as well as hypermesenchymal cells [30] . We have observed subendocardial trophy, or neuroendocrine activity. necrosis in 13-month-old SHHF rats, and a modest in-
The difference in the effect of ACEi vs. MMPi on flammatory cell infiltrate (unpubl. obs.). The increase in collagen a1(I) mRNA levels and LV hypertrophy may MMP-9 observed in the SHHF-13 group may be due to a reflect a difference between these two drugs on angiotensin small number of inflammatory cells present at sites of II levels. Angiotensin II stimulates both myocardial colreactive fibrosis heart. lagen expression and hypertrophy [33] . High plasma levels of the same MMPi used in this study, PD166793, have 4.3. TIMP upregulation recently been shown not to alter plasma renin activity in the paced pig [26] . The increase in plasma renin activity In this study, TIMP-1 and TIMP-2 increased, and TIMPreported in SHHFs [11] suggests that quinapril, but not 4 decreased in SHHFs. The progressive LV dilation that PD166793, reduced angiotensin levels in this study thus occurred in SHHFs indicates that MMP upregulation explaining why ACEi reduced collagen mRNA and LV supercedes increased TIMP-1 and TIMP-2. TIMP upreguhypertrophy while MMPi did not. lation in this study is similar to that reported by Thomas et al. [29] . Whether TIMP-1 and -2 upregulation produces a proportionate decrease in MMP activity is unclear. For 5. Conclusion example, the amount of MMP/ TIMP complex is decreased in the failing human LV, and the ratio of free to bound Both ACEi and MMPi treatment preserved LV systolic TIMP increases [5] . Therefore, increased TIMP protein function, presumably by reducing LV remodeling. Inlevels may not necessarily translate into reduced MMP creased MMP (-2,-9,-13) levels were not always associated activity.
with elevated mRNA levels which indicates that a postFactor(s) involved in TIMP upregulation like that of translation process(es) modulate LV MMP levels. Both MMPs in HF are ill-defined. TIMP-1 has been shown to be ACEi and MMPi reduced fibrosis and normalized MMP/ regulated primarily by cytokines and growth factors [6, 15] , TIMP expression. However, only ACEi reduced collagen and TNFa may be responsible for the induction of TIMP-1 a1(I) mRNA and LV hypertrophy. These results suggest observed in this study. MMP-2 and TIMP-2 share the that ACEi and MMPi efficacy involve different signaling AP-2 promoter, and this may explain why mRNA levels of pathways which converge to produce a similar physiologiboth these genes paralleled each other. TIMP-2 binds to cal effect on LV geometry and function in the SHHF rat. both the active and pro-form of MMP-2, having the greatest affinity among the TIMPs for MMP-2 [6, 15] . Increased TIMP-2 may reflect a compensatory response
